DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 020634/S-068
NDA 020635/S-074
NDA 021721/S-035

SUPPLEMENT APPROVAL

Janssen Pharmaceuticals, Inc.
c/o Janssen Research & Development, LLC
Attention: Andrea F. Kollath, DVM
Director, Global Regulatory Affairs
920 US Highway 202, P.O. Box 300
Raritan, NJ 08869-0602

Dear Dr. Kollath:

We have received your Supplemental New Drug Applications (sNDAs) dated and received August 10, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA or the Act) for the following:

NDA #	Supplement #	Drug Product	Dosage
020634	068	Levaquin (levofloxacin) Tablets	250 mg, 500 mg, and 750 mg
020635	074	Levaquin (levofloxacin) Injection	5mg/mL
021721	035	Levaquin (levofloxacin) Oral Solution	25 mg/mL

These Changes Being Effected supplemental new drug applications provide for revisions to the U.S Prescribing Information (PI) as follows:

- **Section 5, WARNINGS AND PRECAUTIONS**, subsection **5.4 Central Nervous System** has been updated to state the risk of completed suicide, especially in patients with a medical history of depression or an underlying risk factor for depression.

- **Section 6, ADVERSE REACTIONS**, subsection **6.3 Postmarketing Experience** has been updated to include completed suicide, Acute Generalized Exanthematous Pustulosis (AGEP), and fixed drug eruptions.

In addition, the **MEDICATION GUIDE** was revised to clarify language regarding skin rash.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with text for the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Susmita Samanta, Safety Regulatory Project Manager, at (301) 796-0803.

Sincerely,

{See appended electronic signature page}

Joseph Toerner, M.D., M.P.H.
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOSEPH G TOERNER
02/08/2017